Medication info
Bikawons Jeong 10/40 Milligrams

Bikawons Jeong 10/40 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Kips Bio Pharma Co., Ltd.
Appearance
Brownish-red round film-coated tablets
Packaging
30 tablets/Alu-Alu [10 tablets/Alu-Alu x 3]
Approval status
Active

MFDS item code 201903525 · Approved 2019.05.29 · Insurance code 693202160

Summary

Main use
Treatment of essential hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Kips Bio Pharma Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled by monotherapy

  • Primary hypertension
View approved original text

This medication is used to effectively control the blood pressure of patients with primary hypertension whose blood pressure is not adequately controlled by the monotherapy of amlodipine or olmesartan medoxomil.

How to take

Adult dose

Take one tablet once daily with water, with or without food. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with monotherapy with olmesartan medoxomil 20 milligrams. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients in whom this medicine must not be administered, under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. It should not be taken by those allergic to the active ingredients or similar classes of drugs, those who are pregnant or breastfeeding, those with severe liver dysfunction, or certain heart diseases. Caution should be exercised to monitor conditions in patients with low body fluids or sodium, as blood pressure can drop significantly at the early stage of treatment. As excessive dilation of blood vessels may lead to hypotension, it should be used with caution, especially in patients with severe heart valve disease. In patients with severe heart disease, this medication may increase the risk of angina and myocardial infarction, thus caution is warranted. For patients with compromised kidney function, this medication may worsen kidney function, so regular monitoring of kidney function is necessary. Patients with impaired liver function may have delayed metabolism and excretion of this medication, hence caution is advised while taking it. Side effects such as dizziness, headache, hypotension, edema, dyspepsia may occur during treatment, and should any unusual symptoms arise, consultation with healthcare personnel is recommended. Particularly, potassium levels may increase in the blood, so it is important to regularly check potassium levels. This medication may interact with other drugs, so if you are taking other medications, be sure to inform your healthcare personnel. It is advisable to avoid using this medication during pregnancy and for breastfeeding mothers, as it can be transmitted through breast milk and requires discontinuation of breastfeeding or the medication itself. Safety and efficacy in children under 18 years have not been established, thus it is not recommended for use in this age group. Elderly patients may have diminished liver, kidney, and heart function, thus beginning with a lower dose and closely monitoring their condition is advised. In the event of overdose, blood pressure may drop significantly, requiring immediate medical attention for appropriate treatment. This medication should be stored in a sealed container away from direct sunlight and moisture, and out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • hypoesthesia
  • syncope
Show 85 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • epigastric pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • frequency of urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin
  • decreased hematocrit
  • cholelithiasis
  • female breast neoplasm
  • worsening of cerebral infarction
  • gingival bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • insomnia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • vertigo
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to protect it from exposure to air or moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Brownish-red round film-coated tablets

Package unit

30 tablets/Alu-Alu [10 tablets/Alu-Alu x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.